title: Are family physicians using the CHADS₂score? Is it useful for assessing risk of stroke in patients with atrial fibrillation?
abstract: OBJECTIVE
  To assess whether family physicians are using the CHADS(2) (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, and stroke or transient ischemic attack) score in the decision to initiate warfarin therapy to prevent stroke in patients with atrial fibrillation.
  
  
  METHODS
  Retrospective analysis of the medical records of patients with atrial fibrillation.
  
  
  METHODS
  Data were gathered from records at 3 clinics in a primary care network in Edmonton, Alta.
  
  
  METHODS
  The medical records of patients with atrial fibrillation who were currently taking warfarin therapy.
  
  
  METHODS
  Percentage of patients whose CHADS(2) scores indicated warfarin therapy for stroke prophylaxis compared with the actual percentage of patients taking warfarin therapy. Data on patients' age, number of medications, and number of comorbid conditions were also recorded.
  
  
  RESULTS
  Among these patients, 7% had a CHADS(2) score of 0, for which no warfarin therapy was indicated; 21% had a score of 1, for which either acetylsalicylic acid or warfarin was indicated; and 72% had a score of 2 or greater, for which warfarin therapy was indicated. About 80% of patients were taking medication to control their heart rate.
  
  
  CONCLUSIONS
  The CHADS(2) score is not being used in all cases to assess the need for warfarin therapy for preventing stroke in patients with atrial fibrillation. The CHADS(2) score might be of limited use because it is not sensitive enough to stratify patients clearly into high-, intermediate-, and low-risk groups. Although guidelines for stroke prevention should be followed, the CHADS(2) portion of the guidelines might not be the most effective way to assess patients' risk of stroke.
authors.affiliation: University of Alberta, Department of Family Medicine, 205 College Plaza, Edmonton, AB T6G 2C8. doug.klein@ualberta.ca
authors.forename: Douglas
authors.initials: D
authors.lastname: Klein
authors.forename: Max
authors.initials: M
authors.lastname: Levine
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000416:Alberta; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D003661:Decision Support Techniques; D005194:Family Practice; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D018570:Risk Assessment; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin